Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.
2024-02-01 • Lancet Respiratory Medicine
2024-02-01 • Lancet Respiratory Medicine
BACKGROUND Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.
2022-12-22 • New England Journal of Medicine
2022-12-22 • New England Journal of Medicine
BACKGROUND In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current...
Sweeney S, Berry C, Kazounis E, Motta I, Vassall A, et al.
2022-12-07 • PLOS Global Public Health
2022-12-07 • PLOS Global Public Health
Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PR...
Berry C, du Cros PAK, Fielding K, Gajewski S, Kazounis E, et al.
2022-06-13 • Trials
2022-06-13 • Trials
BACKGROUND Globally rifampicin-resistant tuberculosis disease affects around 460,000 people each year. Currently recommended regimens are 9-24 months duration, have poor efficacy and...
Lachenal N, Hewison CCH, Berry C, Mitnick CD, Ahmed SM, et al.
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
INTRODUCTION Drug-resistant tuberculosis (DR-TB) carries significant morbidity and mortality risk. Care of DR-TB in pregnancy is even more challenging. A recent meta-analysis examini...
Berry C, Motta I, Kazounis E, Fielding K, Dodd M, et al.
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
INTRODUCTION Rifamipcin-resistant tuberculosis (RR-TB) affects around 465,000 people each year globally. Current treatment is of 9-20 months’ duration; is toxic and poorly efficaciou...
Wharton-Smith A, Horter SCB, Douch E, Gray NSB, James N, et al.
2021-12-04 • Trials
2021-12-04 • Trials
BACKGROUND Addressing the global burden of multidrug-resistant tuberculosis (MDR-TB) requires identification of shorter, less toxic treatment regimens. Médecins Sans Frontières (MSF)...
Nyang'wa BT, Kloprogge F, Moore DAJ, Bustinduy A, Motta I, et al.
2021-09-06 • BMJ Open
2021-09-06 • BMJ Open
INTRODUCTION Drug-resistant tuberculosis (TB) remains a global health threat, with little over 50% of patients successfully treated. Novel regimens like the ones being studied in the...
INTRODUCTION People living with multidrug-resistant tuberculosis currently have few options for effective treatment and cure. Regimens that are available are toxic, may involve injec...
Nyang'wa BT, LaHood AN, Mitnick CD, Guglielmetti L
2021-05-29 • Trials
2021-05-29 • Trials
When 2020 opened, approximately 11 million new tuberculosis (TB) cases and nearly 1.5 million TB-related deaths were predicted during the year. And, the gap between required and availabl...
Sweeney S, Gomez G, Kitson N, Sinha A, Yatskevich N, et al.
2020-10-10 • BMJ Open
2020-10-10 • BMJ Open
INTRODUCTION Current treatment regimens for multidrug-resistant tuberculosis (MDR-TB) are long, poorly tolerated and have poor outcomes. Furthermore, the costs of treating MDR-TB are...
